A Phase 2a, multicentre, parallel-group, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of XEN-D0501 in the treatment of idiopathic overactive bladder (OAB).
Phase of Trial: Phase II
Latest Information Update: 27 Aug 2014
At a glance
- Drugs XEN D0501 (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Xention
- 16 Nov 2011 Planned number of patients changed from 180 to 300 as reported by European Clinical Trials Database.
- 13 Jun 2011 New trial record